{"id":19297,"date":"2023-06-08T07:35:00","date_gmt":"2023-06-08T07:35:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4123605_AE23605_0"},"modified":"2023-06-08T07:35:00","modified_gmt":"2023-06-08T07:35:00","slug":"qilu-pharmaceutical-announces-trials-in-progress-posters-on-ql1706-in-phase-iii-nsclc-clinical-research-at-asco-2023","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=19297","title":{"rendered":"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

JINAN, China<\/span>, June 8, 2023<\/span> \/PRNewswire\/ — Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706 (iparomlimab\/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma (NSCLC) clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023).<\/p>\n

Study One:
Title: DUBHE-L-304: A randomized, double-blind, multicenter Phase III study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIB NSCLC
Abstract Number: TPS8606
Date of Display: June 4, 2023<\/span><\/p>\n

Nearly 30% of patients with NSCLC are diagnosed with resectable early-stage NSCLC at initial diagnosis. Surgery is the standard treatment for those with early-stage NSCLC, and adjuvant chemotherapy (CT) is commonly used in patients with resectable locally advanced NSCLC. Previous Phase III clinical studies have shown that PD-1\/PD-L1 blockers have good efficacy in the adjuvant therapy with NSCLC. However, the use of PD-1\/PD-L1 blockers as adjuvant therapy remains ineffective in patients with PD-L1-negative NSCLC.<\/p>\n

The DUBHE-L-304 study (NCT05487391) is a double-blind, randomized, placebo-controlled Phase III clinical study. The study plans to enroll 632 patients with completely resected stage II-IIIB NSCLC, without EGFR-sensitive mutations and ALK fusion genes. Patients will receive 16 cycles of either QL1706 or a placebo in combination with 2-4 cycles of adjuvant chemotherapy. The primary endpoints are investigator-assessed disease-free survival (DFS) in the group (PD-L1\u22651%) and investigator-assessed DFS in all patients. The study is being conducted in 61 research centers across China<\/span>. The first patient was enrolled on December 8, 2022<\/span>.<\/p>\n

Study Two:
Title: DUBHE-L-303: A phase III, multicenter, double-blind, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as First-line (1L) therapy for PD-L1 negative advanced or metastatic non-small-cell lung cancer (NSCLC)
Abstract Number: TPS9139
Date of Display: June 4, 2023<\/span><\/p>\n

For patients with locally advanced or metastatic NSCLC with negative driver genes, immune checkpoint inhibitors plus platinum-based chemotherapy have become the standard first-line therapy. Among patients with NSCLC in China<\/span>, those with PD-L1-negative NSCLC (TPS<1%) account for around 40%-50%. Existing standard treatments are less effective in this group, and there is an unmet need for treatment.<\/p>\n

The DUBHE-L-303 study (NCT05690945) is a double-blind, randomized, active-controlled phase III study. The study plans to enroll 650 patients with PD-L1-negative, stage IIIB-IV NSCLC without EGFR\/ALK mutations. Patients will receive four cycles of either QL1706 or tislelizumab plus chemotherapy, followed by maintenance treatment with QL1706 or tislelizumab (QL1706 or tislelizumab plus pemetrexed for non-squamous NSCLC). The primary endpoints include investigator-assessed progression-free survival (PFS) (RECIST 1.1) and overall survival (OS). The study is being conducted at 68 research centers across China<\/span>. The first patient was treated on February 16, 2023<\/span>.<\/p>\n<\/p><\/div>\n

Source: Qilu Pharmaceutical Co., Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"

JINAN, China, June 8, 2023 \/PRNewswire\/ — Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706 (iparomlimab\/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma (NSCLC) clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023). Study One:Title: DUBHE-L-304: A randomized, double-blind, multicenter […]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-19297","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"\nQilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023 - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=19297\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023 - My Blog\" \/>\n<meta property=\"og:description\" content=\"JINAN, China, June 8, 2023 \/PRNewswire\/ — Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706 (iparomlimab\/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma (NSCLC) clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023). Study One:Title: DUBHE-L-304: A randomized, double-blind, multicenter […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=19297\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-08T07:35:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2073821\/QILU_logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023\",\"datePublished\":\"2023-06-08T07:35:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297\"},\"wordCount\":450,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2073821\\\/QILU_logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297\",\"name\":\"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023 - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2073821\\\/QILU_logo.jpg?p=medium600\",\"datePublished\":\"2023-06-08T07:35:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2073821\\\/QILU_logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2073821\\\/QILU_logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19297#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023 - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=19297","og_locale":"en_US","og_type":"article","og_title":"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023 - My Blog","og_description":"JINAN, China, June 8, 2023 \/PRNewswire\/ — Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706 (iparomlimab\/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma (NSCLC) clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023). Study One:Title: DUBHE-L-304: A randomized, double-blind, multicenter […]","og_url":"https:\/\/transmediavictoria.net.au\/?p=19297","og_site_name":"My Blog","article_published_time":"2023-06-08T07:35:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2073821\/QILU_logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=19297#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19297"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023","datePublished":"2023-06-08T07:35:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19297"},"wordCount":450,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19297#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2073821\/QILU_logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=19297","url":"https:\/\/transmediavictoria.net.au\/?p=19297","name":"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023 - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19297#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19297#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2073821\/QILU_logo.jpg?p=medium600","datePublished":"2023-06-08T07:35:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19297#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=19297"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=19297#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/2073821\/QILU_logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/2073821\/QILU_logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=19297#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/19297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19297"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/19297\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}